NASDAQ:VRPX

Virpax Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy VRPX

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jun 03, 2026

Virpax Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 4.66M and sold 0 VRPX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	4.66M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 17, 2024 Buy	Common Stock J-Other	Panis Jaydriane	Director	0 Value: $0
Dec 17, 2024 Buy	Common Stock J-Other	Panis Jaydriane	Director	0 Value: $0
Nov 19, 2024 Buy	Common Stock J-Other	Randhawa Esha	Director	0 Value: $0
Nov 19, 2024 Buy	Common Stock J-Other	Randhawa Esha	Director	0 Value: $0
Nov 18, 2024 Buy	Common Stock J-Other	Chaudhry Usama Officer	Officer	0 Value: $0
Nov 18, 2024 Buy	Common Stock J-Other	Chaudhry Usama Officer	Officer	0 Value: $0
Jul 05, 2024 Buy	Common Stock J-Other	Su Judy	Director	0 Value: $0
Jul 05, 2024 Buy	Common Stock J-Other	Su Judy	Director	0 Value: $0
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Field Katharyn Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Common Stock J-Other	Field Katharyn	Director	0 Value: $0
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Field Katharyn Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Common Stock J-Other	Field Katharyn	Director	0 Value: $0
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Herman Gary L Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Dhaliwal Jatinder Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Common Stock J-Other	Herman Gary L	Director	0 Value: $0
Jul 05, 2024 Buy	Common Stock J-Other	Dhaliwal Jatinder	Director	0 Value: $0
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Herman Gary L Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Stock Option (right to buy) A-Award	Dhaliwal Jatinder Director	Director	2 500 Value: $1K
Jul 05, 2024 Buy	Common Stock J-Other	Herman Gary L	Director	0 Value: $0
Jul 05, 2024 Buy	Common Stock J-Other	Dhaliwal Jatinder	Director	0 Value: $0
Jan 29, 2024 Buy	Stock Option (right to buy) A-Award	Singh Vanila Director	Director	25 000 Value: $8K
Jan 29, 2024 Buy	Stock Option (right to buy) A-Award	Shah Vinay Chief Financial Officer	C-Suite Officer	112 000 Value: $35.6K
Jan 29, 2024 Buy	Stock Option (right to buy) A-Award	Jambulingam Thani Director	Director	25 000 Value: $8K
Jan 29, 2024 Buy	Stock Option (right to buy) A-Award	Mathias Sheila Chief Scientific Officer	Officer	112 000 Value: $35.6K
Jan 29, 2024 Buy	Stock Option (right to buy) A-Award	Dubin Michael F Director	Director	25 000 Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VIRPAX PHARMACEUTICALS, INC.

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...

Read Full Profile Here